2 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayercancer, neoplasmActive, not recruitingPhase 32026-07-07NCT04464226
BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC TreatmentDigestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorderRecruitingNot stated2022-09-29NCT04673955